Cited by 174RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

In vivo delivery of RNAi with lipid-based nanoparticles

Huang, Leaf, Liu, Yang·2011·Annual Review of Biomedical Engineering

Abstract

RNA interference (RNAi) technology represents a fundamentally new category of treatments for human disease by addressing targets that are traditionally considered undruggable with existing medicines. The major challenge for RNAi-based therapy is the delivery system that meets human therapeutic needs. Therefore, engineering vectors with good delivery efficiency and safety profile is an intense area of research. Lipid-based nanoparticles for RNAi have yielded successful advances in vivo and to an extent in clinical trials. In this review, we discuss the barriers in developing lipid-based nanoparticles for in vivo RNAi and different strategies to overcome them. Rational designs that address safety concerns and ensure effective delivery will aid the translation of engineered lipid-based nanoparticles toward the clinic in the foreseeable future.

Integrity signals

Registry

Crossref · 10.1146/annurev-bioeng-071910-124709

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LNPs encapsulate and protect RNAs from degradation during circulation and deliver RNA payloads to target organs following systemic administration.

    “The exceptional properties of LNPs for RNA delivery include, but are not limited to, the encapsulation and protection of RNAs from degradation during circulation, as well as the delivery of RNA payloads to the target organ following systemic administration.[18, 54, 61]”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Huang, L., & Liu, Y.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Annual Review of Biomedical Engineering
Published
2011-08-15
Volume
13
Issue
1
Pages
507-530
ISSN
  • 1523-9829 (ISSN-L)
  • 1545-4274
OpenAlex
W2127833150
Cited by
174
References
115
Citations by year
2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 9 · 2017: 12 · 2016: 17 · 2015: 8 · 2014: 18 · 2013: 34 · 2012: 21
FWCI
2.18
Type
journal article
Language
en
Open access
closed
Locations
  • Annual Review of Biomedical Engineering (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (CA129421, R01CA129835, R01CA129421, R01CA149363, CA149363, CA129835)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
RNA interference, lipid nanoparticles, gene silencing, therapeutic vectors, vector design, vector safety, clinical translation, undruggable targets
MeSH terms
Algorithms, Drug Carriers, Genetic Vectors, Humans, Liposomes, Neoplasms, Pharmacokinetics, Polyethylene Glycols, Virus Diseases, Genetic Therapy, Genetic Diseases, Inborn, RNA Interference, RNA, Small Interfering, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review